94 related articles for article (PubMed ID: 38505140)
1. Spesolimab in the Management of Generalized Pustular Psoriasis With Concurrent Bullous Pemphigoid and Psoriasis.
Teshima R; Saito-Sasaki N; Hitaka T; Sawada Y
Cureus; 2024 May; 16(5):e60331. PubMed ID: 38883056
[TBL] [Abstract][Full Text] [Related]
2. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis.
Johnston A; Xing X; Wolterink L; Barnes DH; Yin Z; Reingold L; Kahlenberg JM; Harms PW; Gudjonsson JE
J Allergy Clin Immunol; 2017 Jul; 140(1):109-120. PubMed ID: 28043870
[TBL] [Abstract][Full Text] [Related]
3. Generalized Pustular Psoriasis and Systemic Organ Dysfunctions.
Teshima R; Saito-Sasaki N; Sawada Y
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892457
[TBL] [Abstract][Full Text] [Related]
4. The role of interleukin-36 in health and disease states.
Sugiura K; Fujita H; Komine M; Yamanaka K; Akiyama M
J Eur Acad Dermatol Venereol; 2024 May; ():. PubMed ID: 38779986
[TBL] [Abstract][Full Text] [Related]
5. Spesolimab rapidly treats generalized pustular psoriasis and improves the skin immune microenvironment in Chinese patients.
Lu J; Yu Q; Huang D; Hu Y; Zhong X; Zheng J; Ding Y; Gao Y; Li Y; Shi Y
Clin Immunol; 2024 Jun; 265():110280. PubMed ID: 38880199
[No Abstract] [Full Text] [Related]
6. Spesolimab improved pustules on the palms and soles that were refractory to tumor necrosis factor inhibitors and interleukin-17 inhibitors in a patient with generalized pustular psoriasis: A case report.
Suzuki S; Kamata M; Ito M; Watanabe A; Uchida H; Chijiwa C; Azuma S; Hayashi K; Sugiura K; Tada Y
J Dermatol; 2024 Jun; ():. PubMed ID: 38874489
[No Abstract] [Full Text] [Related]
7. The expanding horizon of anti-IL-36 therapy.
Heymann WR
J Am Acad Dermatol; 2024 Apr; 90(4):714-715. PubMed ID: 38296196
[No Abstract] [Full Text] [Related]
8. Therapeutic Potential of Spesolimab-Sbzo in the Management of Generalized Pustular Psoriasis Flares in Adults: Evidence to Date.
Rega F; Trovato F; Bortone G; Pellacani G; Richetta AG; Dattola A
Psoriasis (Auckl); 2024; 14():23-27. PubMed ID: 38505140
[TBL] [Abstract][Full Text] [Related]
9. Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis.
Morita A; Choon SE; Bachelez H; Anadkat MJ; Marrakchi S; Zheng M; Tsai TF; Turki H; Hua H; Rajeswari S; Thoma C; Burden AD
Dermatol Ther (Heidelb); 2023 Jan; 13(1):347-359. PubMed ID: 36333618
[TBL] [Abstract][Full Text] [Related]
10. The role of the interleukin-36 axis in generalized pustular psoriasis: a review of the mechanism of action of spesolimab.
Hawkes JE; Visvanathan S; Krueger JG
Front Immunol; 2023; 14():1292941. PubMed ID: 38077370
[TBL] [Abstract][Full Text] [Related]
11. Exploring the Clinical Assessment, Guidelines, and Options for the Treatment of Generalized Pustular Psoriasis [Podcast].
Song EJ; Liu C
Clin Cosmet Investig Dermatol; 2023; 16():2911-2917. PubMed ID: 37915421
[TBL] [Abstract][Full Text] [Related]
12. Spesolimab for the Treatment of Generalized Pustular Psoriasis.
Bernardo D; Thaçi D; Torres T
Drugs; 2024 Jan; 84(1):45-58. PubMed ID: 38114719
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of acrodermatitis continua of Hallopeau coexisting with generalized pustular psoriasis with spesolimab: a case report.
Wen P; Liu C; Wang T; Jiang X; Wang P; Wang S
Front Immunol; 2024; 15():1338285. PubMed ID: 38464535
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
